Innovations and recent trends in the treatment of ADHD

Vishal Madaan; Shannon Kinnan; Joan Daughton; Christopher J. Kratochvil

doi:10.1586/14737175.6.9.1375

Innovations and recent trends in the treatment of ADHD

Vishal Madaan, Shannon Kinnan, Joan Daughton, Christopher J. Kratochvil

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

Original language	English (US)
Pages (from-to)	1375-1385
Number of pages	11
Journal	Expert Review of Neurotherapeutics
Volume	6
Issue number	9
DOIs	https://doi.org/10.1586/14737175.6.9.1375
State	Published - Sep 2006

Keywords

Atomoxetine
Attention-deficit hyperactivity disorder
Modafinil
NRP-104
Pharmacotherapy
Stimulants
Transdermal

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology
Pharmacology (medical)

Access to Document

10.1586/14737175.6.9.1375

Cite this

@article{ce1940c9171946cba952a6a972c217db,

title = "Innovations and recent trends in the treatment of ADHD",

abstract = "Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.",

keywords = "Atomoxetine, Attention-deficit hyperactivity disorder, Modafinil, NRP-104, Pharmacotherapy, Stimulants, Transdermal",

author = "Vishal Madaan and Shannon Kinnan and Joan Daughton and Kratochvil, {Christopher J.}",

note = "Funding Information: Christopher J Kratochvil is supported by NIMH Grant 5K23MH06612701A1. He also receives grant support from Eli Lilly (IN, USA), McNeil (NJ, USA) and Cephalon (PA, USA), is a consultant for Eli Lilly, Shire (PA, USA), Cephalon, Organon (NJ, USA), AstraZeneca (DE, USA), Boehringer-Ingel-heim (Germany) and Pfizer (NY, USA), and a member of the Eli Lilly speaker{\textquoteright}s bureau.",

year = "2006",

month = sep,

doi = "10.1586/14737175.6.9.1375",

language = "English (US)",

volume = "6",

pages = "1375--1385",

journal = "Expert Review of Neurotherapeutics",

issn = "1473-7175",

publisher = "Expert Reviews Ltd.",

number = "9",

}

TY - JOUR

T1 - Innovations and recent trends in the treatment of ADHD

AU - Madaan, Vishal

AU - Kinnan, Shannon

AU - Daughton, Joan

AU - Kratochvil, Christopher J.

N1 - Funding Information: Christopher J Kratochvil is supported by NIMH Grant 5K23MH06612701A1. He also receives grant support from Eli Lilly (IN, USA), McNeil (NJ, USA) and Cephalon (PA, USA), is a consultant for Eli Lilly, Shire (PA, USA), Cephalon, Organon (NJ, USA), AstraZeneca (DE, USA), Boehringer-Ingel-heim (Germany) and Pfizer (NY, USA), and a member of the Eli Lilly speaker’s bureau.

PY - 2006/9

Y1 - 2006/9

N2 - Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

AB - Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

KW - Atomoxetine

KW - Attention-deficit hyperactivity disorder

KW - Modafinil

KW - NRP-104

KW - Pharmacotherapy

KW - Stimulants

KW - Transdermal

UR - http://www.scopus.com/inward/record.url?scp=33750182472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750182472&partnerID=8YFLogxK

U2 - 10.1586/14737175.6.9.1375

DO - 10.1586/14737175.6.9.1375

M3 - Review article

C2 - 17009924

AN - SCOPUS:33750182472

SN - 1473-7175

VL - 6

SP - 1375

EP - 1385

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

IS - 9

ER -

Innovations and recent trends in the treatment of ADHD

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this